Medical Condition News

RSS

Mechanism linking brain activity to sleep discovered

Washington State University researchers have discovered the mechanism by which the brain switches from a wakeful to a sleeping state. The finding clears the way for a suite of discoveries, from sleeping aids to treatments for stroke and other brain injuries.

15 Sep 2010

Canadian Cancer Society, POGO collaborate to improve quality of life in childhood cancer survivors

The Canadian Cancer Society and the Pediatric Oncology Group of Ontario (POGO) today announced that they have joined forces to improve the quality of outcomes for children and adolescents diagnosed with cancer and their families.

15 Sep 2010

ACT receives patent for RPE cells to treat retinal degeneration

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it will be issued U.S. Patent Numbers 7,795,025 and 7,794,704 on Tuesday, September 14th, which continue to extend the company's patent portfolio covering its retinal pigment epithelial (RPE) cell programs.

15 Sep 2010

microRNA 451 enhances treatment response in stomach cancer patients: Research

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

15 Sep 2010

USF receives grant for studying ways to protect fetal brain from maternal infection

University of South Florida (USF) neuroscientists have been awarded a $400,000 federal grant to study ways of protecting the developing fetal brain from the damaging effects of maternal infections, a suspected cause for certain types of autism.

15 Sep 2010

Researchers identify risk gene for schizophrenia

An international team of researchers has identified a risk gene for schizophrenia, including a potentially causative mutation, using genome-wide association data-mining techniques and independent replications.

15 Sep 2010

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.

15 Sep 2010

$Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy$

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

15 Sep 2010

FDA approves Krystexxa drug to treat gout

The U.S. Food and Drug Administration approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy.

15 Sep 2010

Researchers unveil watercress compound can block pathway for cancer development

The research, unveiled at a press conference today (14 September 2010), shows that the watercress compound is able to interfere with the function of a protein which plays a critical role in cancer development.

15 Sep 2010

Scientists discover study of calcium deposits helps effective breast cancer diagnosis

SCIENTISTS have discovered for the first time that studying calcium deposits in the breast, often detected through screening, could help doctors diagnose breast cancer more effectively.The study, published in the British Journal of Cancer today (Wednesday), examined the relationship between the composition of these deposits found in breast tissue and the malignancy of a tumour.

15 Sep 2010

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced results from a pre-clinical pharmacokinetic study showing the ability of NexACT to enable rectal delivery of biologics, such as human antibodies.

15 Sep 2010

Dana-Farber doctor hosts live program on Twitter to discuss head and neck cancers

The recent news that Michael Douglas has been diagnosed with stage 4 throat cancer has raised public awareness of head and neck cancer. What causes throat cancer and what are the symptoms? Are there ways to prevent or reduce the risk of throat cancer? How is the human papillomavirus (HPV) related to oral cancer?

14 Sep 2010

Cetaphil launches Restoraderm for management of eczema and atopic dermatitis skin

The Cetaphil® brand, the #1 dermatologist-recommended brand of cleansers and moisturizers announced the launch of Cetaphil® Restoraderm® products, formulated specifically for the needs of eczema and atopic dermatitis skin. Cetaphil® Restoraderm® Skin Restoring Body Wash and Skin Restoring Moisturizer soothes itching associated with skin affected by eczema and atopic dermatitis.

14 Sep 2010

CSC launches new educational program to enhance lymphoma patient, physician communication

The Cancer Support Community (CSC), uniting The Wellness Community and Gilda's Club Worldwide, announced today the launch of Framing Life With Lymphoma, a new educational program designed to enhance lymphoma patient and physician communication.

14 Sep 2010

GenVec completes initial milestone in collaboration with Novartis

GenVec, Inc. today announced that it has achieved the first milestone in its collaboration with Novartis, related to the development of treatments for hearing loss and balance disorders. The milestone was triggered by the successful completion of certain preclinical development activities.

14 Sep 2010

Data from Phase II trial of zanolimumab in PTCL published in British Journal of Haematology

TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma.

14 Sep 2010

Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology

Gentium S.p.A. today announced that two posters and one oral presentation on defibrotide will be presented at the 33rd World Congress of International Society of Hematology to be held at the ICC Jerusalem International Convention Center in Jerusalem, Israel, October 10-13, 2010.

14 Sep 2010

Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that patient screening in its DSC127 Phase 2 trial in diabetic foot ulcer healing will be completed tomorrow, and that enrollment in the trial will conclude on September 30. This randomized, double-blind, placebo controlled study of up to 75 patients will look at the percentage of diabetic ulcers completely healed over a 12-week period, among other outcomes.

14 Sep 2010

Mini-Psych School 2010 program to focus on mental health in children, youth

For the past five years, the Douglas Mental Health University Institute has been offering the Mini-Psych School, the only public education program of its kind in Quebec. This year, the program will be focussing on mental health in children and youth.

14 Sep 2010

Medical Condition News

Mechanism linking brain activity to sleep discovered

Canadian Cancer Society, POGO collaborate to improve quality of life in childhood cancer survivors

ACT receives patent for RPE cells to treat retinal degeneration

microRNA 451 enhances treatment response in stomach cancer patients: Research

USF receives grant for studying ways to protect fetal brain from maternal infection

Researchers identify risk gene for schizophrenia

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

FDA approves Krystexxa drug to treat gout

Researchers unveil watercress compound can block pathway for cancer development

Scientists discover study of calcium deposits helps effective breast cancer diagnosis

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

Dana-Farber doctor hosts live program on Twitter to discuss head and neck cancers

Cetaphil launches Restoraderm for management of eczema and atopic dermatitis skin

CSC launches new educational program to enhance lymphoma patient, physician communication

GenVec completes initial milestone in collaboration with Novartis

Data from Phase II trial of zanolimumab in PTCL published in British Journal of Haematology

Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology

Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end

Mini-Psych School 2010 program to focus on mental health in children, youth

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News